Gangliosides: therapeutic agents or therapeutic targets?

Bibliography

• SAUVE GJ, SARAGOVI HU, GREENE MI: Reovirus receptors. Adv. Virus Res. (1993) 42:325–341.
   PubMedGoogle Scholar
• YOSHIDA S, FUKUMOTO S, KAWAGUCHI H et al.: Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. (2001) 61(10):4244–4252.
   PubMed Web of Science ®Google Scholar
• KAUCIC K, ETUE N, LAFLEUR B, WOODS W, LADISCH S: Neuroblastomata of infancy exhibit a characteristic ganglioside pattern. Cancer (2001) 91(4):785–793.
   PubMedGoogle Scholar
• NAKATSUJI Y, MILLER RH: Selective cell-cycle arrest and induction of apoptosis in proliferating neural cells by ganglioside GM3. Exp. Neura (2001) 168(2):290–299.
   PubMedGoogle Scholar
• SLEVIN M, KUMAR S, HE X, GAFFNEY J: Physiological concentrations of gangliosides GM1, GM2 and GM3 differentially modify basic-fibroblast-growth-factor-induced mitogenesis and the associated signalling pathway in endothelial cells. hat. Cancer(1999) 82(3):412–423.
   Google Scholar
• MARQUINA G, WAKI H, FERNANDEZ LE et al.: Gangliosides expressed in human breast cancer. Cancer Res. (1996) 56(22):5165–5171.
   PubMed Web of Science ®Google Scholar
• MUSSELLI C, LIVINGSTON PO, RAGUPATHI G: Keyhole limpet haemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J. Cancer Res. Clin. Oncol. (2001) 127\(Suppl. 2):R20–R26.
   Google Scholar
• ••An extensive review of the considerablework the Memorial Sloan Kettering has done with ganglioside cancer vaccines.
   Google Scholar
• HOUGHTON AN, MINTZER D, CORDON-CARDO C et al.: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a Phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA (1985) 82(4):1242–1246.
   PubMedGoogle Scholar
• KUSHNER BH, KRAMER K, CHEUNG NK: Phase II trial of the antiG(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.Oncol. (2001) 19(22):4189–4194.
   Google Scholar
• HAKOMORI S: Tumour malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. (1996) 56(23):5309–5318.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive look at the possibleimplication of ganglioside overexpression in cancer.
   Google Scholar
• PANES MK, EL-ABBADI M, MANFREDI MG et al: N-butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours. Br. J. Cancer (2001) 84(8):1107–1114.
   PubMedGoogle Scholar
• NOLL EN, UN J, NAKATSUJI Y, MILLER RH, BLACK PM: GM3 as a novel growth regulator for human gliomas. Exp. Neurol. (2001) 168(2):300–309.
   PubMedGoogle Scholar
• VISCO V, LUCANIA G, SANSOLINI T et al.: Expression of GM3 microdomains on the surfaces of murine fibroblasts correlates with inhibition of cell proliferation. Histochem. Cell Biol. (2000) 113(1):43–50.
   PubMedGoogle Scholar
• FERRARI G, ANDERSON BL, STEPHENS RM, KAPLAN DR, GREENE LA: Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. Biol. Chem. (1995) 270(7):3074–3080.
   Google Scholar
• •Potential mechanism for the oft-observed neuroprotective effect of GM1.
   Google Scholar
• SABEL BA, SLAVIN MD, STEIN DG: GM1 ganglioside treatment facilitates behavioural recovery from bilateral brain damage. Science (1984) 225(4659):340–342.
   PubMedGoogle Scholar
• •In vivo evidence of GM1 neuroprotection.
   Google Scholar
• HADJICONSTANTINOU M, NEFF NH: GM1 ganglioside: in vivo and M vitro tropic actions on central neurotransmitter systems. Neurochem. (1998) 70(4):1335–1345.
   PubMedGoogle Scholar
• •Critical review of the possible uses of GM1 as a neuroprotective drug.
   Google Scholar
• GEISLER FH, COLEMAN WP, GIANCINTO G, DEVINDER P, GROUP SS: The Sygen multicenter acute spinal cord injury study. Spine (2001) 26(24S):S87-S98 Summary statement S99–S100.
   Google Scholar
• NO AUTHOR LISTED: Ganglioside GM1 in acute ischaemic stroke. The SASS Trial. Stroke (1994) 25(6):1141–1148.
   PubMedGoogle Scholar
• ALTER M: GM1 ganglioside for acute ischaemic stroke. Trial design issues. Ann. NY Acad. Sci. (1998) 845:391–401.
   PubMedGoogle Scholar
• MIYAGI T, WADA T, IWAMATSU A et al.: Molecular cloning and characterisation of a plasma membrane-associated sialidase specific for gangliosides. Biol. Chem. (1999) 274(8):5004–5011.
   Google Scholar
• CHOO-SMITH LP, GARZON-RODRIGUEZ W, GLABE CG, SUREWICZ WK: Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside- containing membrane vesicles. J. Biol. Chem. (1997) 272(37):22987–22990.
   PubMedGoogle Scholar
• YU J, LANGRIDGE WH: A plant-based multicomponent vaccine protects mice from enteric diseases. Nat. Biotechnol.(2001) 19(6):548–552.
   PubMed Web of Science ®Google Scholar
• •Interesting use of a ganglioside ligand as a dietary vaccine.
   Google Scholar
• SORICE M, GAROFALO T, SANSOLINI T et al.: Overexpression of monosialoganglioside GM3 on lymphocyte plasma membrane in patients with HIV infection.' AIDS Human Retrovirol. (1996) 12(2):112–119.
   PubMedGoogle Scholar
• MATSUDA K, TAKI T, HAMANAKA S et al.: Glycosphingolipid compositions of human T-lymphotropic virus Type I (HTLV-I) and human immunodeficiency virus (HIV)-infected cell lines. Biochim. Biophys. Acta (1993) 1168(2):123–129.
   PubMedGoogle Scholar
• MISASI R, SORICE M, GRIGGI T et al: GM3 as a target of antilymphocytic ganglioside antibodies in AIDS patients. Immunol. Immunopathol. (1993) 67(3):216–223.
   PubMedGoogle Scholar
• AUCI DL, CHICE SM, DURKIN HG, MURALI MR: Constitutive production of PAI-II and increased surface expression of GM1 ganglioside by peripheral blood monocytes from patients with AIDS: evidence of monocyte activation in vivo. Leukocyte Biol. (1992) 52(3):282–286.
   PubMedGoogle Scholar
• FURUKAWA K, AKAGI T, NAGATA Y et al.: GD2 ganglioside on human T-lymphotropic virus Type I-infected T cells: possible activation of 13-1,4-N-acetylgalactosaminyltransferase gene by p4Otax. Proc. Natl. Acad. Sci. USA (1993) 90(5):1972–1976.
   PubMedGoogle Scholar
• AGARWAL MK, NETER E: Effect of selected lipids and surfactants on immunogenicity of several bacterial antigens. Immunol. (1971) 107(5):1448–1456.
   Google Scholar
• ZIEGLER-HEITBROCK HW, KAFFERLEIN E, HAAS JG et al.: Gangliosides suppress tumour necrosis factor production in human monocytes. Immunol. (1992) 148(6):1753–1758.
   Google Scholar
• LU P, SHAROM FJ: Gangliosides are potent immunosuppressors of IL-2-mediated T cell proliferation in a low protein environment. Immunology (1995) 86(3):356–363.
   PubMedGoogle Scholar
• LI R, GAGED, MCKALLIP R, LADISCHS: Structural characterisation and in vivo immunosuppressive activity of neuroblastoma GD2. Clycoconjugate(1996) 13(3):385–389.
   PubMedGoogle Scholar
• RAPPORT MM, DONNENFELD H, BRUNNER W, HUNGUND B, BARTFELD H: Ganglioside patterns in amyotropic lateral sclerosis brain regions. Ann. Neurol. (1985) 18(1):60–67.
   PubMedGoogle Scholar
• SVENNERHOLM L, BOSTROM K, FREDMAN P et al.: Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim. Biophys. Acta (1994) 1214(2):115–123.
   PubMed Web of Science ®Google Scholar
• ••Useful study of ganglioside expressionpatterns in spinal cord and peripheral nervous system.
   Google Scholar
• YUKI N, YOSHINO H, SATO S, MIYATAKE T: Acute axonal polyneuropathy associated with antiGM1 antibodies following Campylobacter enteritis. Neurology (1990) 40(12):1900–1902.
   PubMed Web of Science ®Google Scholar
• HEYNINGEN SV: Cholera toxin: interaction of subunits with ganglioside GM1. Science (1974) 183(125):656–657.
   PubMedGoogle Scholar
• BREMER EG, HAKOMORI S, BOWEN-POPE DF, RAINES E, ROSS R: Ganglioside-mediated modulation of cell growth, growth factor binding and receptor phosphorylation. J. Biol. Chem. (1984) 259(11):6818–6825.
   PubMedGoogle Scholar
• MUTOH T, TOKUDA A, MIYADAIT, HAMAGUCHI M, FUJIKI N: Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Natl. Acad. Sri. USA (1995) 92(11):5087–5091.
   PubMedGoogle Scholar
• SHAROM FJ, CHIU AL, CHU JW: Membrane gangliosides modulate interleukin-2-stimulated T lymphocyte proliferation. Biochim. Biophys. Acta (1991) 1094(1):35–42.
   PubMedGoogle Scholar
• SVENNERHOLM L: Chemical structure of normal human brain and Tay-Sachs gangliosides. Biochem. Biophys. Res. Comm. (1962) 9:436–441.
   PubMed Web of Science ®Google Scholar
• TAI T, PAULSON JC, CAHAN LD, IRIE RF: Ganglioside GM2 as a human tumour antigen (OFA-I-1). Proc. Nati Acad. Sri. USA (1983) 80(17):5392–5396.
   PubMed Web of Science ®Google Scholar
• YUYAMA Y, DOHI T, MORITA H, FURUKAWA K, OSHIMA M: Enhanced expression of GM2/GD2 synthase mRNA in human gastrointestinal cancer. Cancer (1995) 75(6):1273–1280.
   PubMedGoogle Scholar
• CAHAN LD, IRIE RE SINGH R, CASSIDENTI A, PAULSON JC: Identification of a human neuroectodermal tumour antigen (OFA-I-2) as ganglioside 1222 GD2. Proc. Nati Acad. Sci. USA (1982) 79(24):7629–7633.
   PubMedGoogle Scholar
• SCHULZ G, CHERESH DA, VARKI NM et al.: Detection of ganglioside GD2 in tumour tissues and sera of neuroblastoma patients. Cancer Res. (1984) 44(12):5914–5920.
   PubMedGoogle Scholar
• PROBSTMEIER R, MICHELS M, FRANZ T, CHAN BM, PESHEVA P: Tenascin-R interferes with integrin-dependent oligodendrocyte precursor cell adhesion by a ganglioside-mediated signalling mechanism. Eur. I Neurosci.(1999) 11(7):2474–2488.
   PubMedGoogle Scholar
• PUKEL CS, LLOYD KO, TRAVASSOS LR et al.: GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J. Exp. Med. (1982) 155(4):1133–1147.
   Google Scholar
• ZHANG S, CORDON-CARDO C, ZHANG HS et al.: Selection of tumour antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer (1997) 73(1):42–49.
   PubMedGoogle Scholar
• NORIHISA Y, MCVICAR DW, GHOSH P et al: Increased proliferation, cytotoxicity and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3). Irurnunol. (1994) 152(2):485–495. Published erratum appears in J. Immunol.(1994) 153(2):910
   Google Scholar
• DE MARIA R, LENTI L, MALISAN F et al.: Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science (1997) 277(5332):1652–1655. Published erratum appears in Science (1998) 280(5362):363
   Google Scholar
• •Description of the novel role of GD3 in intracellular events leading to apoptosis.
   Google Scholar
• MILJAN EA, MEUILLET EJ, MANIA-FARNELL B et al.: Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J. Biol. Chem. (2002) 277(12):10108–10113.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI T, KUSUNOKI S, KAIDA K, SHIINA M, KANAZAWA I: Guillain-Barre syndrome associated with IgG monospecific to ganglioside GD lb. Neurology (2001) 56(9):1227–1229.
   PubMedGoogle Scholar
• LADISCH S, BECKER H, ULSH L: Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim. Biophys. Acta (1992) 1125(2):180–188.
   PubMed Web of Science ®Google Scholar
• MIRKIN BL, CLARK SH, ZHANG C: Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B. Cell Proli (2002) 35(2):105–115.
   PubMedGoogle Scholar